Buy Reasoning
WC8 was on my radar as a high-beta lithium explorer with a compelling near-term catalyst setup. The thesis rested on three pillars: a clear mining permit for the Tabba Tabba project, a DFS expected in 2026, and a balance sheet with ~A$48.5m cash — meaning no near-term dilution risk.
I built the position across six tranches:
| Date | Price | Units | Amount |
|---|---|---|---|
| 2025-11-19 | $0.280 | 14,285 | -$4,019.75 |
| 2025-11-19 | $0.280 | 21,428 | -$6,019.79 |
| 2025-11-24 | $0.270 | 18,518 | -$5,019.81 |
| 2025-12-10 | $0.315 | 15,873 | -$5,019.95 |
| 2025-12-18 | $0.305 | 16,129 | -$4,939.30 |
| 2026-01-19 | $0.445 | 35,000 | -$15,604.95 |
| Total | avg ~$0.335 | 121,233 | -$40,623.55 |
The initial entries in late November were triggered by price action around the $0.27–$0.28 level, where I observed consistent buying across sessions. The December additions were averaging into a consolidation zone, and the final tranche in January at $0.445 followed a breakout on strong volume ahead of anticipated news flow on the DFS and the Bolt Cutter discovery update.
My view was that the lithium cycle was in the early stages of a structural recovery, and that WC8's Pilbara asset represented one of the cleaner hard-rock exploration stories — high-grade, well-funded, and increasingly de-risked with each drill result.
Sell Reasoning
I exited the position in three tranches as the price moved into my target zone and technical signals started to turn:
| Date | Price | Units | Proceeds |
|---|---|---|---|
| 2025-12-04 | $0.260 | 18,867 | +$4,885.47 |
| 2025-12-09 | $0.275 | 20,000 | +$5,480.05 |
| 2026-01-28 | $0.405 | 82,366 | +$33,318.20 |
| Total | avg ~$0.360 | 121,233 | +$43,683.72 |
The first two sells in December were tactical — price had rallied from the entry zone but showed signs of distribution near $0.26–$0.28. I trimmed the early tranches to reduce cost base and manage risk while keeping the bulk of the position for the expected January catalyst.
The final exit on 28 January at $0.405 came after a strong rally following the Bolt Cutter assay results. Price ran into resistance at the $0.40–$0.42 range on three consecutive sessions with increasing sell-side volume. I interpreted this as smart money distribution and closed the remaining position at market.
Net result: +$3,060.17 (+7.5% on total capital deployed)
The trade worked, but the execution was imperfect. Adding the large $0.445 tranche in January inflated the average cost significantly. Had I maintained more discipline on position sizing in the final tranche, the return on capital would have been meaningfully higher.